Technology

Mersana has developed highly differentiated and innovative antibody-drug conjugate (ADC) platforms, with both cytotoxic and immunostimulatory payloads, that allow for customization and optimization of ADCs for a given target and indication.  As a result, we are designing ADCs to overcome the limitations of first-generation platforms by delivering therapeutics with greater efficacy and tolerability to address the unmet medical needs of people living with cancer.

Pipeline

We are leveraging our proprietary technology platforms to build a robust pipeline of ADCs with the potential to meaningfully improve the lives of people living with cancer. We are pursuing a multiprong strategy for treating cancer with both cytotoxic and immunostimulatory ADCs.